Over the past 70 years, psychedelic research for treating mental illness, particularly addictions, has evolved from early work with LSD in the 1950s and 1960s to recent neuroscience-driven studies. Recent developments include the use of MDMA in psychotherapy and ketamine as a treatment for mental illnesses. New research explores brain mechanisms underlying these therapeutic effects. The field faces challenges in advancing research and clinical application.
Psychedelic-assisted psychotherapies for substance use disorders are transitioning from experimental research into clinical practice. This paper reviews the current evidence, highlighting promising results for treating alcohol and opioid use disorders with psilocybin and ibogaine, respectively, while noting methodological limitations and the need for larger controlled trials. It discusses challenges in integrating these therapies into existing healthcare systems, including regulatory hurdles, therapist training, and ensuring equitable access. The authors argue that careful implementation and continued research are necessary to translate findings into effective, real-world treatments.